Five Prime enters Osteoarthritis and Pulmonary Fibrosis Collaboration with Centocor
- Category: More News
- Published on Thursday, 04 January 2007 02:00
- Hits: 3571
SAN FRANCISCO, CA, USA | Jan 03, 2007 | Five Prime Therapeutics, Inc. today announced a worldwide collaborative research and license agreement with Centocor Research and Development Inc. The collaboration will focus on novel therapeutic products to treat osteoarthritis and pulmonary fibrosis. Under the collaboration, FivePrime will screen its comprehensive protein library against cell-based assays directed to osteoarthritis and fibrosis and Centocor will have exclusive rights to the proteins and targets identified in these screens.
FivePrime will receive an upfront payment of $15 million, comprised of cash and an equity investment by Johnson and Johnson Development Corporation (JJDC), and two years research funding from Centocor. Centocor will have exclusive worldwide rights to develop and commercialize products and targets discovered during the research term in exchange for future milestones and royalties. Further details of the agreement have not been disclosed.
“With Centocor as a partner in these disease areas, we should be able to move the products of our discovery platform into clinical trials faster and more effectively”, commented Lewis T. “Rusty” Williams, FivePrime’s founder and Executive Chairman.
“Centocor has a long-standing commitment to innovative biotherapeutics”, added Gail Maderis, President and CEO of FivePrime. “We are extremely pleased to be working with a group that shares our enthusiasm for the tremendous potential of novel biologic therapies. Additionally, we welcome JJDC to our premier group of investors.”
A key component of the collaboration is FivePrime’s comprehensive, rapid protein discovery system. FivePrime’s protein screening library contains essentially all human secreted proteins and their receptors, including many that are unavailable in public collections. FivePrime screens its protein library in complex, primary cell assays with a level of precision, speed and thoroughness previously achievable only in small molecule screening. Using technologies for rapid in vivo validation of hits from its screens, FivePrime aims to reduce time from idea to an Investigational New Drug to less than three years.
SOURCE: Five Prime Therapeutics, Inc.